retatrutide clinical trial availability Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation VisualAbstract: Retatrutide reduces body weight

GLP-1 medications address the metabolic consequence by reducing appetite, slowing gastric emptying, and improving insulin sensitivity

Constipation means contents are backing up in the large intestine, which creates additional fermentation opportunity and can increase gas production throughout the entire digestive tract

Results can last up to a year or more, with optional maintenance treatments available every 6 to 12 months to extend the benefits

Our team can help with documentation, coordination, and prior authorization support when appropriate

The differences between postmeal gastric emptying and the housekeeping function of interdigestive MMC activity are illustrated in Fig